^
Association details:
| Biomarker: | SETBP1 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC
Published date:
08/02/2023
Excerpt:
Among the aggregated NSCLC samples, a total of 13 (11.9%) of 109 had SETBP1 mutations. Kaplan-Meier results demonstrated that SETBP1-MUT NSCLC patients presented a markedly improved ICI survival benefit than wild-type patients (median survival time: NA vs. 6.3 months, Log-rank test P = 0.013; Figure 4A).
DOI:
https://doi.org/10.18632/aging.204913
